Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From
FDA
Adverse Event Reporting System
International Journal of Dermatology | September 24, 2025 | Volume: 65 | Issue: 4 | Pages: 825-827
10.1111/ijd.70082
| PMID 40990361